Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has said that the Australian Full Federal Court in Victoria has upheld on appeal, the exclusivity of its basic patent covering atorvastatin, the active ingredient in Lipitor.
Subscribe to our email newsletter
The ruling, the culmination of a lawsuit filed in 2005 by generic drug manufacturer Ranbaxy, preserves Lipitor’s patent coverage in Australia through May 2012. Ranbaxy can appeal the decision.
The court found that a proposed Ranbaxy generic product would infringe Pfizer’s basic Lipitor patent. A second patent covering the calcium salt of atorvastatin, which expires in September 2012, was ruled invalid by the court. Pfizer has the opportunity to appeal that ruling. The Australian decision will not impact ongoing Lipitor patent actions in other countries, including the US.